Terms: = Lymphoma AND FGFR1, CEK, 2260, ENSG00000077782, P11362, FLT2, CD331, H3, HBGFR, FGFBR, H5, KAL2, H2, BFGFR, N-SAM, H4 AND Prognosis
68 results:
1. Expression and Clinical Significance of CD30 and CD56 in Lymphoblastic lymphoma: A Retrospective Analysis on Paraffin-Embedded Tissues by Immunohistochemistry.
Li S; Zheng S; Huang X; Zhang W; Liu F; Cao Q
Fetal Pediatr Pathol; 2024; 43(2):111-122. PubMed ID: 38213180
[No Abstract] [Full Text] [Related]
2. Extracellular vesicles as biomarkers for AIDS-associated non-Hodgkin lymphoma risk.
Martínez LE; Magpantay LI; Guo Y; Hegde P; Detels R; Hussain SK; Epeldegui M
Front Immunol; 2023; 14():1259007. PubMed ID: 37809067
[TBL] [Abstract] [Full Text] [Related]
3. ATF4 renders human T-cell acute lymphoblastic leukemia cell resistance to fgfr1 inhibitors through amino acid metabolic reprogramming.
Zhang ZJ; Wu QF; Ren AQ; Chen Q; Shi JZ; Li JP; Liu XY; Zhang ZJ; Tang YZ; Zhao Y; Yao NN; Zhang XY; Liu CP; Dong G; Zhao JX; Xu MJ; Yue YQ; Hu J; Sun F; Liu Y; Ao QL; Zhou FL; Wu H; Zhang TC; Zhu HC
Acta Pharmacol Sin; 2023 Nov; 44(11):2282-2295. PubMed ID: 37280363
[TBL] [Abstract] [Full Text] [Related]
4. Pemigatinib for the treatment of myeloid/lymphoid neoplasms with
Freyer CW; Hughes ME; Carulli A; Bagg A; Hexner E
Expert Rev Anticancer Ther; 2023 Apr; 23(4):351-359. PubMed ID: 36927350
[TBL] [Abstract] [Full Text] [Related]
5. Proteasome inhibition targets the KMT2A transcriptional complex in acute lymphoblastic leukemia.
Kamens JL; Nance S; Koss C; Xu B; Cotton A; Lam JW; Garfinkle EAR; Nallagatla P; Smith AMR; Mitchell S; Ma J; Currier D; Wright WC; Kavdia K; Pagala VR; Kim W; Wallace LM; Cho JH; Fan Y; Seth A; Twarog N; Choi JK; Obeng EA; Hatley ME; Metzger ML; Inaba H; Jeha S; Rubnitz JE; Peng J; Chen T; Shelat AA; Guy RK; Gruber TA
Nat Commun; 2023 Feb; 14(1):809. PubMed ID: 36781850
[TBL] [Abstract] [Full Text] [Related]
6. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
[TBL] [Abstract] [Full Text] [Related]
7. A truncated derivative of fgfr1 kinase cooperates with FLT3 and KIT to transform hematopoietic stem cells in syndromic and de novo AML.
Cai B; Liu Y; Chong Y; Mori SF; Matsunaga A; Zhang H; Fang X; Chang CS; Cowell JK; Hu T
Mol Cancer; 2022 Jul; 21(1):156. PubMed ID: 35906694
[TBL] [Abstract] [Full Text] [Related]
8. Hypo-trimethylation of Histone H3 Lysine 4 and Hyper-tri/dimethylation of Histone H3 Lysine 27 as Epigenetic Markers of Poor prognosis in Patients with Primary Central Nervous System lymphoma.
Kim HG; Kim MS; Lee YS; Lee EH; Kim DC; Lee SH; Kim YZ
Cancer Res Treat; 2022 Jul; 54(3):690-708. PubMed ID: 34793663
[TBL] [Abstract] [Full Text] [Related]
9. VISTA and PD-L1 synergistically predict poor prognosis in patients with extranodal natural killer/T-cell lymphoma.
He HX; Gao Y; Fu JC; Zhou QH; Wang XX; Bai B; Li PF; Huang C; Rong QX; Ping LQ; He YX; Mao JY; Chen X; Huang HQ
Oncoimmunology; 2021 Apr; 10(1):1907059. PubMed ID: 33889438
[TBL] [Abstract] [Full Text] [Related]
10. Hypereosinophilic syndromes - An enigmatic group of disorders with an intriguing clinical spectrum and challenging treatment.
Helbig G; Klion AD
Blood Rev; 2021 Sep; 49():100809. PubMed ID: 33714638
[TBL] [Abstract] [Full Text] [Related]
11. Apoptotic regulator BCL-2 blockade as a potential therapy in classical Hodgkin lymphoma.
Gamboa-Cedeño AM; Díaz M; Cristaldo N; Otero V; Schutz N; Fantl D; Cugliari S; Zerga M; Rojas-Bilbao E; Jauk F; García Rivello H; Nuñez M; Ranuncolo SM
Life Sci; 2021 Mar; 268():118979. PubMed ID: 33421528
[TBL] [Abstract] [Full Text] [Related]
12. Checkpoint regulator B7x is epigenetically regulated by HDAC3 and mediates resistance to HDAC inhibitors by reprogramming the tumor immune environment in colorectal cancer.
Li Y; Liu Y; Zhao N; Yang X; Li Y; Zhai F; Zang X; Cui W
Cell Death Dis; 2020 Sep; 11(9):753. PubMed ID: 32934224
[TBL] [Abstract] [Full Text] [Related]
13. Update on CML-Like Disorders.
Cross NCP
Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S101-S102. PubMed ID: 32862848
[TBL] [Abstract] [Full Text] [Related]
14. [Expression and Clinical Significance of Soluble B7-H3 in Patient with Secondary Hemophagocytic Lymphohistiocytosis].
Lyu X; Wang Y; Wang LL; Yin GL; Liu LL; Duan LM; Tian T; Xu J; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Jun; 28(3):1006-1011. PubMed ID: 32552973
[TBL] [Abstract] [Full Text] [Related]
15. Lack of Targetable FGFR2 Fusions in Endemic Fluke-Associated Cholangiocarcinoma.
Kongpetch S; Jusakul A; Lim JQ; Ng CCY; Chan JY; Rajasegaran V; Lim TH; Lim KH; Choo SP; Dima S; Popescu I; Duda DG; Kukongviriyapan V; Khuntikeo N; Pairojkul C; Rozen SG; Tan P; Teh BT
JCO Glob Oncol; 2020 Apr; 6():628-638. PubMed ID: 32315234
[TBL] [Abstract] [Full Text] [Related]
16. Discovery of a first-in-class EZH2 selective degrader.
Ma A; Stratikopoulos E; Park KS; Wei J; Martin TC; Yang X; Schwarz M; Leshchenko V; Rialdi A; Dale B; Lagana A; Guccione E; Parekh S; Parsons R; Jin J
Nat Chem Biol; 2020 Feb; 16(2):214-222. PubMed ID: 31819273
[TBL] [Abstract] [Full Text] [Related]
17. Expression of co-inhibitory molecules B7-H4 and B7-H1 in Epstein-Barr virus positive diffuse large B-cell lymphoma and their roles in tumor invasion.
Jiang Y; Lin J; Zhang J; Lu S; Wang C; Tong Y
Pathol Res Pract; 2019 Dec; 215(12):152684. PubMed ID: 31679792
[TBL] [Abstract] [Full Text] [Related]
18. [The 8p11 myeloproliferative syndrome: a review of recent literature].
Kirito K
Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
[TBL] [Abstract] [Full Text] [Related]
19. Aberrant differential expression of EZH2 and H3K27me3 in extranodal NK/T-cell lymphoma, nasal type, is associated with disease progression and prognosis.
Liu J; Liang L; Huang S; Nong L; Li D; Zhang B; Li T
Hum Pathol; 2019 Jan; 83():166-176. PubMed ID: 30218753
[TBL] [Abstract] [Full Text] [Related]
20. Clinical outcomes of myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (fgfr1) rearrangement.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2018 Sep; 23(8):470-477. PubMed ID: 29486661
[TBL] [Abstract] [Full Text] [Related]
[Next]
